Axsome Therapeutics (AXSM) Misses Q1 EPS by 22c

Axsome Therapeutics (NASDAQ: AXSM) reported Q1 EPS of ($1.44), $0.22 worse than the analyst estimate of ($1.22). Revenue for the quarter came in at $75 million versus the consensus estimate of $74 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Target raises full-year sales forecast amid ongoing turnaround drive
• Futu Holdings Limited (FUTU) Tops Q2 EPS by 23c